Raymond James Upgrades Keryx Biopharmaceuticals (KERX) to Outperform
Tweet
Share
E-mailGet Alerts KERX Hot Sheet
Price: $3.36 --0%
Rating Summary:
6 Buy, 10 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
6 Buy, 10 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Raymond James upgraded Keryx Biopharmaceuticals (NASDAQ: KERX) from Market Perform to Outperform with a price target of $6.00.
For an analyst ratings summary and ratings history on Keryx Biopharmaceuticals click here. For more ratings news on Keryx Biopharmaceuticals click here.
Shares of Keryx Biopharmaceuticals closed at $3.34 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wells Fargo Upgrades Portland General Electric Company (POR) to Overweight
- KeyBanc Upgrades Innovage Holding Corp (INNV) to Overweight
- Morgan Stanley Upgrades Ternium S.A. (TX) to Overweight
Create E-mail Alert Related Categories
UpgradesRelated Entities
Raymond JamesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
